Januvia approved as add-on to insulin treatment

Januvia (sitagliptin) can now be prescribed as an add-on to insulin (with or without metformin) for patients with type II diabetes in whom diet and exercise, plus a stable dose of insulin, do not provide adequate glycaemic control. In a 24-week study in 305 patients, addition of sitagliptin to insulin significantly improved glycaemic parameters compared with placebo, with no major effect on body weight. When Januvia is combined with insulin, reduction of the insulin dose may be appropriate to reduce the risk of hypoglycaemia.

View Januvia drug record

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

NICE recommends SGLT2 inhibitors for chronic kidney disease

NICE recommends SGLT2 inhibitors for chronic kidney disease

Updated NICE guidance on type II diabetes recommends...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Avoid routinely offering antidepressants for 'less severe' depression, says NICE in draft guidance
Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...